COVID-19 Restrictions to remain in place at our hospital

We would like to remind you that the restrictions currently in place across the NHS will remain for the foreseeable future. This includes limitations on visiting patients, and infection control measures such as wearing face masks, temperature checks and maintaining social distancing when at our hospital.

Dr Saif Huda

About Saif Huda

Dr Saif Huda completed undergraduate medical training in Liverpool in 2005 and completed neurology specialist training at The Walton Centre in 2017. Between 2012-2015 he undertook a DPhil in neuroimmunology at The University of Oxford before completing a post-CCT fellowship in neuromyelitis optica in 2018.  

Dr Huda is the clinical lead for the UK NMOSD highly specialised service. My team and I provide a multidisciplinary service for patients with NMOSD and myelin oligodendrocyte glycoprotein associated disease (MOGAD) across the United Kingdom. I am also a Multiple Sclerosis specialist and have expertise in antibody-mediated central nervous system disorders.  

He provides a weekly MS clinic and acute ward referral service to Glan Clywd Hospital, North Wales.  In addition to general neurology clinics he also holds a monthly CNS autoimmune clinic.  

Dr Huda’s group’s research focuses on immune tolerance mechanisms and biomarkers in NMOSD and MOG-antibody associated disease, particularly clinical and serological biomarkers that help predict relapse risk and prognosis. They are also interested in immune tolerance mechanisms and identifying novel symptomatic therapies that can improve patient quality of life. Dr Huda is a principal investigator for several Phase III clinical trials in NMOSD, MOGAD, and autoimmune encephalitis.      

Speciality

Neuromyelitis optica spectrum disorders (NMOSD) 

Multiple sclerosis (MS) 

Antibody-mediated CNS disease 

Myasthenia gravis  

Qualifications

MBChB  

MRCP(Neuro)  

DPhil(Oxon) 

Clinical/research interests

Clinical 

Neuromyelitis optica spectrum disorder (NMOSD) 

Myelin oligodendrocyte glycoprotein associated disease (MOGAD) 

Multiple Sclerosis 

Antibody-mediated central nervous system disorders 

Research 

NMOSD and MOGAD - clinical and serological biomarkers that help predict relapse risk and prognosis 

Immune tolerance mechanisms and identifying novel symptomatic therapies that can improve patient quality of life 

Autoimmune encephalitis    

Membership of professional regional and national bodies

Royal College of Physicians London 

Association of British Neurologists 

American Academy of Neurology 

Related Services

Neurology

The Neurology service provides specialist care to patients across Cheshire, Merseyside, North Wales and the Isle of Man. 

Multiple sclerosis

Multiple Sclerosis (MS) is the most common potentially disabling disease of the central nervous system affecting young adults.

Page last updated: 14 July 2021